The emerging roles and mechanism of N6-methyladenosine (m(6)A) modifications in urologic tumours progression

Prostate cancer (PCa), bladder cancer (BC), and renal cell cancer (RCC) are the most common urologic tumours in males. N6-methyladenosine (m(6)A), adenosine N6 methylation, is the most prevalent RNA modification in mammals. Increasing evidence suggests that m(6)A plays a crucial role in cancer devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Wenhao, Zhao, Renshan, Guan, Xiaomin, Wang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239868/
https://www.ncbi.nlm.nih.gov/pubmed/37284313
http://dx.doi.org/10.3389/fphar.2023.1192495
Descripción
Sumario:Prostate cancer (PCa), bladder cancer (BC), and renal cell cancer (RCC) are the most common urologic tumours in males. N6-methyladenosine (m(6)A), adenosine N6 methylation, is the most prevalent RNA modification in mammals. Increasing evidence suggests that m(6)A plays a crucial role in cancer development. In this review, we comprehensively analyzed the influence of m(6)A methylation on Prostate cancer, bladder cancer, and renal cell cancer and the relationship between the expression of relevant regulatory factors and their development and occurrence, which provides new insights and approaches for the early clinical diagnosis and targeted therapy of urologic malignancies.

Ejemplares similares